According to the instruction for the Nomination Committee adopted by the AGM in 2024, the Nomination Committee for the Diagonal Bios AGM 2025 shall consist of four members, representing the three largest shareholders on September 30th together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.

Based on the above, the Nomination Committee for the AGM 2025 has been established to consist of the following persons:

• Svante Olofsson, represents own shareholdings, Chairman of the Committee
• Juha Kauppinen, represents own shareholdings
• Ylber Rexhepi, represents own shareholdings
• Kerstin Jakobsson, Observer, Chairman Diagonal Bio AB

The company shall publish the names of the Nomination Committee members at least six months before the  Annual General Meeting. If, within two months of the Annual General Meeting, a shareholder's voting power exceeds that of the shareholder with the fewest votes on the Committee, the new shareholder may request a position, replacing the member with the lowest voting power. The Chairman of the Board convenes the Nomination Committee for a first meeting, at which the Nomination Committee elects a chairman from among its members. The Chairman can participate in the Nomination Committee as an observer.

Shareholders wishing to submit proposals or comments to the Nomination Committee may do so via email to: valberedning@diagonalbio.com . To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than 28 February  2025. The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website.

The task of the Nomination Committee prior to the AGM is to prepare and submit proposals regarding the Chairman of the AGM, the number of Board members elected by the AGM, the Chairman and other Board members elected by the AGM, the fees and other remuneration for each of the Board members elected by the AGM and for members of Board committees, the number of auditors, the auditors, the fee for auditors and if applicable new principles for appointing a Nomination Committee, as well as instructions for the Nomination Committee.

The Nomination Committee shall have the right, within a budget approved by the Board, to charge the company with costs for, e.g., recruitment consultants and other consultants that are required for the Nomination Committee to be able to fulfil its assignment and may also co-opt members to the Nomination Committee if deemed appropriate; co-opted member shall not, however, have the right to vote in the nomination committee. There is no remuneration of the Nomination Committee.

For information about Diagonal Bio AB, please contact:

Karin Wehlin, CEO

Phone: +46 703 052 488

Mail: kw@diagonalbio.com

www.diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

E-post: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.